SHR-1894 / Jiangsu Hengrui Pharma - LARVOL DELTA

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of a Single Subcutaneous Injection of SHR-1894 in Healthy Subjects: A Randomised, Double-Blind, Placebo-Controlled Phase I Clinical Study (ChiCTR) - P1 | N=40 | Sponsor: West China Hospital of Sichuan University; Suzhou Shengdiya Biopharmaceutical Co., Ltd.

New P1 trial

A Phase I Study of Single Subcutaneous Dose of SHR-1894 in Healthy Subjects (clinicaltrials.gov) - P1 | N=40 | Recruiting | Sponsor: Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Not yet recruiting ➔ Recruiting

Enrollment open • Dermatitis • Dermatology • Immunology

A Phase I Study of Single Subcutaneous Dose of SHR-1894 in Healthy Subjects (clinicaltrials.gov) - P1 | N=40 | Not yet recruiting | Sponsor: Suzhou Suncadia Biopharmaceuticals Co., Ltd.

New P1 trial • Dermatitis • Dermatology • Immunology